Could less medicine keep eczema under control? trial tests spacing out injections
NCT ID NCT06004986
Summary
This study is testing whether adults with atopic eczema (atopic dermatitis) that is already well-controlled can safely take their dupilumab medication less often. Researchers will randomly assign 216 participants to receive their standard injection every 2 weeks, or to try extending the time between doses to every 3 or 4 weeks. The main goal is to see if less frequent dosing is just as effective at controlling eczema, while potentially reducing costs and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam University Medical Centers
RECRUITINGAmsterdam, North Holland, 1105 AZ, Netherlands
Contact
-
Erasmus Medical Center
NOT_YET_RECRUITINGRotterdam, South Holland, 3015 GD, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.